NASDAQ:VYGR - Voyager Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $15.38
  • Forecasted Upside: 77.45 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$8.67
▲ +0.17 (2.00%)
1 month | 3 months | 12 months
Get New Voyager Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VYGR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VYGR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$15.38
▲ +77.45% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Voyager Therapeutics in the last 3 months. The average price target is $15.38, with a high forecast of $26.00 and a low forecast of $10.00. The average price target represents a 77.45% upside from the last price of $8.67.
Buy
The current consensus among 12 polled investment analysts is to buy stock in Voyager Therapeutics. This rating has held steady since November 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/30/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/21/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
1/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/13/2021Canaccord GenuityReiterated RatingBuy$14.00Low
i
12/23/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$15.00 ➝ $10.00N/A
i
Rating by C. Duncan at Cantor Fitzgerald
12/23/2020Raymond JamesDowngradeOutperform ➝ Market PerformN/A
i
11/11/2020BTIG ResearchLower Price Target$31.00 ➝ $18.00High
i
11/11/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
i
11/10/2020WedbushLower Price TargetOutperform$19.00 ➝ $13.00High
i
11/10/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$10.00High
i
11/10/2020Raymond JamesDowngradeStrong-Buy ➝ Outperform$28.00 ➝ $17.00High
i
10/13/2020WedbushLower Price TargetHold ➝ Outperform$24.00 ➝ $19.00High
i
8/14/2020Chardan CapitalReiterated RatingHold$15.00Medium
i
Rating by Gbola Amusa at Chardan Capital
8/12/2020WedbushReiterated RatingBuy$24.00Low
i
8/4/2020HC WainwrightLower Price TargetBuy$18.00 ➝ $14.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
5/13/2020NomuraReiterated RatingBuy$16.00Low
i
5/8/2020Chardan CapitalReiterated RatingHold$15.00Low
i
Rating by G. Amusa at Chardan Capital
4/15/2020Morgan StanleyLower Price TargetEqual Weight$14.00 ➝ $13.00Low
i
3/30/2020Nomura SecuritiesLower Price TargetBuy$37.00 ➝ $16.00High
i
3/19/2020BenchmarkInitiated CoverageBuy$18.00High
i
3/6/2020Chardan CapitalReiterated RatingHold$20.00High
i
Rating by Gbola Amusa at Chardan Capital
3/4/2020HC WainwrightLower Price TargetBuy$26.00 ➝ $18.00Medium
i
3/4/2020Morgan StanleyLower Price TargetEqual Weight$15.00 ➝ $14.00Medium
i
Rating by Jeffrey Hung at Morgan Stanley
3/4/2020WedbushLower Price TargetOutperform$34.00 ➝ $27.00High
i
Rating by D. Nierengarten at Wedbush
2/5/2020OppenheimerInitiated CoverageOutperform$26.00High
i
11/24/2019Evercore ISIReiterated RatingHold$18.00Medium
i
11/6/2019WedbushReiterated RatingOutperformMedium
i
Rating by D. Nierengarten at Wedbush
11/6/2019CowenReiterated RatingBuyHigh
i
Rating by Phil Nadeau at Cowen Inc
10/15/2019CowenReiterated RatingBuyLow
i
10/11/2019Morgan StanleyLower Price TargetEqual Weight$28.00 ➝ $26.00Low
i
Rating by Jeffrey Hung at Morgan Stanley
8/13/2019Nomura SecuritiesReiterated RatingBuy$37.00High
i
8/12/2019HC WainwrightReiterated RatingBuy$26.00Medium
i
7/12/2019Morgan StanleyBoost Price TargetEqual Weight$21.00 ➝ $28.00Medium
i
6/20/2019Nomura SecuritiesBoost Price TargetBuy$26.00 ➝ $37.00High
i
6/18/2019WedbushBoost Price TargetOutperform$27.00 ➝ $36.00High
i
5/6/2019HC WainwrightReiterated RatingBuy$22.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
3/5/2019Cantor FitzgeraldInitiated CoverageOverweight$27.00High
i
Rating by C. Duncan at Cantor Fitzgerald
2/27/2019CowenReiterated RatingBuyHigh
i
1/15/2019HC WainwrightReiterated RatingBuy$21.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
1/10/2019Chardan CapitalReiterated RatingNeutralMedium
i
Rating by G. Amusa at Chardan Capital
1/8/2019BTIG ResearchLower Price TargetBuy ➝ Positive$23.00Low
i
11/30/2018HC WainwrightSet Price TargetBuy$25.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
11/9/2018HC WainwrightSet Price TargetBuy$25.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
11/8/2018Robert W. BairdLower Price TargetOutperform ➝ Outperform$31.00 ➝ $27.00High
i
11/8/2018Morgan StanleySet Price TargetHold$13.00High
i
Rating by Jeffrey Hung at Morgan Stanley
11/8/2018WedbushReiterated RatingOutperform$18.00 ➝ $28.00High
i
Rating by D. Nierengarten at Wedbush
9/10/2018Morgan StanleyDowngradeOverweight ➝ EqualHigh
i
9/10/2018Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$27.00High
i
9/10/2018BTIG ResearchReiterated RatingBuy ➝ Buy$32.00Medium
i
8/8/2018HC WainwrightSet Price TargetBuy$30.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
7/17/2018Canaccord GenuityReiterated RatingBuy$31.00High
i
Rating by Sumant Kulkarni at Canaccord Genuity
7/17/2018HC WainwrightSet Price TargetBuy$30.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/21/2018Chardan CapitalReiterated RatingHold$30.00High
i
6/7/2018BTIG ResearchReiterated RatingBuy$32.00Low
i
6/6/2018Canaccord GenuitySet Price TargetBuy$35.00Low
i
Rating by Sumant Kulkarni at Canaccord Genuity
6/4/2018HC WainwrightInitiated CoverageBuy$30.00High
i
Rating by D. Chattopadhyay at HC Wainwright
5/29/2018Canaccord GenuitySet Price TargetBuy$35.00High
i
Rating by Sumant Kulkarni at Canaccord Genuity
5/13/2018BTIG ResearchReiterated RatingBuyHigh
i
5/11/2018WedbushUpgradeNeutral ➝ OutperformHigh
i
Rating by D. Nierengarten at Wedbush
5/10/2018Canaccord GenuitySet Price TargetBuy$35.00High
i
Rating by Sumant Kulkarni at Canaccord Genuity
4/9/2018Canaccord GenuitySet Price TargetBuy$35.00High
i
Rating by Sumant Kulkarni at Canaccord Genuity
3/14/2018Canaccord GenuitySet Price TargetBuy ➝ Buy$36.00 ➝ $35.00High
i
Rating by Sumant Kulkarni at Canaccord Genuity
3/12/2018WedbushDowngradeOutperform ➝ Neutral$29.00High
i
Rating by D. Nierengarten at Wedbush
3/12/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ Buy$40.00High
i
Rating by Charles Duncan at Piper Jaffray Companies
3/11/2018BTIG ResearchReiterated RatingBuy$32.00High
i
2/21/2018WedbushBoost Price TargetOutperform$22.00 ➝ $29.00High
i
2/21/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$36.00 ➝ $39.00High
i
2/2/2018Morgan StanleyInitiated CoverageOverweight ➝ OverweightHigh
i
1/23/2018Canaccord GenuityReiterated RatingBuy$26.00Low
i
Rating by Sumant Kulkarni at Canaccord Genuity
12/19/2017BTIG ResearchInitiated CoverageBuy$32.00High
i
11/28/2017Piper Jaffray CompaniesReiterated RatingOverweight$28.00Medium
i
Rating by Charles Duncan at Piper Jaffray Companies
11/20/2017WedbushReiterated RatingOutperform$22.00 ➝ $26.00N/A
i
11/15/2017Canaccord GenuitySet Price TargetBuy$26.00N/A
i
Rating by Sumant Kulkarni at Canaccord Genuity
10/31/2017Chardan CapitalReiterated RatingHold$17.00N/A
i
Rating by Gbola Amusa at Chardan Capital
10/31/2017CowenReiterated RatingBuyN/A
i
10/31/2017WedbushReiterated RatingOutperform ➝ Positive$36.00 ➝ $31.00N/A
i
10/30/2017Robert W. BairdInitiated CoverageOutperform ➝ Outperform$31.00N/A
i
10/27/2017Canaccord GenuityInitiated CoverageBuy ➝ Buy$35.00N/A
i
10/23/2017Stifel NicolausReiterated RatingBuy ➝ Buy$20.00 ➝ $31.00N/A
i
10/12/2017Raymond JamesInitiated CoverageOutperform ➝ Outperform$35.00N/A
i
9/10/2017Chardan CapitalReiterated RatingHoldMedium
i
Rating by Gbola Amusa at Chardan Capital
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$12.00High
i
8/8/2017CowenReiterated RatingBuyLow
i
7/28/2017Stifel NicolausInitiated CoverageBuy$20.00High
i
6/27/2017Stifel NicolausReiterated RatingBuy$33.00High
i
5/10/2017WedbushReiterated RatingOutperform$36.00Medium
i
3/16/2017WedbushReiterated RatingOutperform$36.00Medium
i
3/16/2017Chardan CapitalReiterated RatingNeutral ➝ Neutral$13.00Low
i
Rating by Gbola Amusa at Chardan Capital
3/1/2017Nomura InstinetInitiated CoverageBuy ➝ Buy$31.00N/A
i
3/1/2017Nomura SecuritiesInitiated CoverageBuyN/A
i
1/20/2017CowenReiterated RatingBuyN/A
i
1/20/2017WedbushReiterated RatingOutperform$36.00N/A
i
12/8/2016CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
12/8/2016Chardan CapitalSet Price TargetPositive ➝ Hold$17.73 ➝ $11.00N/A
i
12/8/2016WedbushReiterated RatingOutperform$36.00N/A
i
11/13/2016Piper Jaffray CompaniesReiterated RatingBuy$37.00N/A
i
Rating by joshua schimmer at Piper Jaffray Companies
11/10/2016WedbushReiterated RatingOutperform$36.00N/A
i
11/10/2016CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
8/11/2016WedbushReiterated RatingOutperform$36.00N/A
i
8/11/2016Piper Jaffray CompaniesSet Price TargetBuy$37.00N/A
i
Rating by joshua schimmer at Piper Jaffray Companies
7/14/2016Stifel NicolausInitiated CoverageBuy ➝ Buy$33.00N/A
i
6/22/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
6/22/2016CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
6/22/2016WedbushReiterated RatingOutperform$36.00N/A
i
5/20/2016Wells Fargo & CompanyInitiated CoverageOutperformN/A
i
5/12/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
4/30/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
3/20/2016WedbushReiterated RatingOutperform$36.00N/A
i
Rating by David Nierengarten at Wedbush
3/18/2016CowenReiterated RatingBuyN/A
i
Rating by Phil Nadeau at Cowen Inc
3/18/2016Piper Jaffray CompaniesReiterated RatingBuy$37.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
1/25/2016Chardan CapitalUpgradeSell ➝ Neutral$20.00 ➝ $15.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
(Data available from 1/20/2016 forward)
Voyager Therapeutics logo
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and alpha-synuclein program for synucleinopathies, Parkinson's disease, Lewy Body Dementia, and multiple system atrophy. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $8.67
$8.52
$8.80

50 Day Range

MA: $8.12
$7.15
$9.28

52 Week Range

Now: $8.67
$6.26
$14.62

Volume

457,907 shs

Average Volume

416,760 shs

Market Capitalization

$324.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Voyager Therapeutics?

The following equities research analysts have issued stock ratings on Voyager Therapeutics in the last year: Benchmark Co., BTIG Research, Canaccord Genuity, Cantor Fitzgerald, Chardan Capital, HC Wainwright, Morgan Stanley, Nomura, Nomura Securities, Oppenheimer Holdings Inc., Raymond James, Wedbush, Wells Fargo & Company, and Zacks Investment Research.

What is the current price target for Voyager Therapeutics?

13 Wall Street analysts have set twelve-month price targets for Voyager Therapeutics in the last year. Their average twelve-month price target is $15.38, suggesting a possible upside of 77.4%. Oppenheimer Holdings Inc. has the highest price target set, predicting VYGR will reach $26.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $10.00 for Voyager Therapeutics in the next year.

What is the current consensus analyst rating for Voyager Therapeutics?

Voyager Therapeutics currently has 6 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VYGR will outperform the market and that investors should add to their positions of Voyager Therapeutics.

What other companies compete with Voyager Therapeutics?

How do I contact Voyager Therapeutics' investor relations team?

Voyager Therapeutics' physical mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company's listed phone number is 857-259-5340 and its investor relations email address is pcox@vygr.com. The official website for Voyager Therapeutics is www.voyagertherapeutics.com.